Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
Objective: To review one-year exploratory efficacy data from the ND0612 BeyoND study. Background: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion…Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel
Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…Cellular Modeling of Tyrosine Hydroxylase Deficiency Recapitulates Patient Phenotypes and Response to Treatment.
Objective: Characterize a new cellular model of Tyrosine Hydroxylase deficiency (THD) based on induced pluripotent stem cells (iPSCs) to better understand the pathophysiology and test…CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson’s disease (PD): a meta-analysis
Objective: A meta-analysis of PGIC results was performed using combined data from 3 different studies of CVT-301 in patients with PD over a total of…Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients
Objective: The objectives of this study were to find predictive factors for early dropout from levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD)…Effects of freezing gait and medication on postural control during prolonged standing in individuals with Parkinson’s disease
Objective: To analyze the effects of freezing of gait (FoG) and medication on postural adjustments during prolonged standing in individuals with Parkinson's disease (PD). Background:…CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Objective: Development of a treatment for nocturnal and early morning OFF symptomology in Parkinson’s disease. Background: Levodopa Parkinson’s disease (PD) treatment is limited by its…Levodopa responsive gait dynamics in ON- and OFF-state freezing of gait in Parkinson’s disease
Objective: To determine which spatiotemporal gait parameters respond to levodopa in Parkinson’s patients with levodopa ON- and OFF-state gait freezing. Background: Levodopa-ON-state gait freezing is…Deep brain stimulation in Parkinson’s disease
Objective: Study the various clinical, electrophysiological and therapeutic parameters of operated patients. Evaluate the effectiveness of deep brain stimulation of STN in Parkinson's disease. Background:…Validation of a real- time monitoring system to detect motor symptoms in patients with Parkinson´s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Our aim was to analyze the ability of system to combine information on OFF periods, falls and dyskinesias of patients with PD. Background: Levodopa…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 57
- Next Page »